Uniqe Mode of Action
70% of neurotransmission occurs via glutamate, which is the main neurotransmitter in CNS, involved in memory and learning processes. Glutamate neurotransmission is mediated by the N-methyl-D-aspartate (NMDA) receptors (ref.1).
In Alzheimer’s disease the glutamatergic signalling is disturbed, resulting in neuronal cell death and impaired cognitive function (ref.2).
Ebixa (memantine) is a voltage dependent, moderate-affinity uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, indicated for the treatment of moderate to severe Alzheimer’s disease. Ebixa restores physiological glutamatergic signalling through the NMDA receptors by reducing background noise, leading to improved memory and learning (ref.3).
View the flash of the Unique Mode of Action
References:
1. H. Lundbeck A/S, Data on file, Ebixa EPAR
2. Sucher et al. Trends Pharmacol Sci 1996;17:348-355
3. Parson et al. Drugs News Perspect 1998;11:523-569